To address the issue of resistance to EGFR-TKI in EGFR-mutated NSCLC patients, the preclinical effectiveness of REGN5093-M114, a novel antibody-drug conjugate targeting c-MET in c-MET-driven patient-derived models, was recently investigated (111). This evidence concerns the gene MET and non-small cell lung carcinoma.